Market Access | Getting therapies in patients' hands

Market Access

Man listening to podcast featuring Alice Valder Curran

Unpacking Trump’s executive order on drug pricing, with Alic...

Jonah Comstock welcomed back Alice Valder Curran to the podcast to pick apart Trump's Executive Order order piece by piece.

News

FDA resurrects Satsuma's nasal migraine treatment

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi has been given the go-ahead by the agency.

News

Lilly hit as PBM drops Zepbound, but retains Wegovy

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.

News

US is planning $500m project on 'universal vaccines;' WSJ

The US will spend $500m to develop universal vaccines against multiple virus variants, while planned changes to testing rules are raising concerns.

News

a person's arm with skin lesion triaging tool against the skin

Skin Analytics' dermatology AI backed for NHS use

An AI-powered tool for triaging patients with suspicious skin lesions, developed by Skin Analytics, will be used by the NHS to reduce waiting times.

News

Lilly hit as PBM drops Zepbound, but retains Wegovy

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.

News

US is planning $500m project on 'universal vaccines;' WSJ

The US will spend $500m to develop universal vaccines against multiple virus variants, while planned changes to testing rules are raising concerns.

News

Skin Analytics' dermatology AI backed for NHS use

An AI-powered tool for triaging patients with suspicious skin lesions, developed by Skin Analytics, will be used by the NHS to reduce waiting times.

News

FDA resurrects Satsuma's nasal migraine treatment

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi has been given the go-ahead by the agency.

News

Lilly hit as PBM drops Zepbound, but retains Wegovy

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.

Press Releases

News

Immunocore's rare eye cancer drug backed by NICE

Patients in England with a rare form of eye cancer will be able to access Kimmtrak, a TCR therapy from Immunocore, after NICE changes its position.

News

2019-Gene-Therapy-Muscular-Dystrophy_ProgFeature_IMG

Solid Biosciences acquires AavantiBio, conducts $75 million ...

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a

Views & Analysis

Market Access

Unpacking Trump’s executive order on drug pricing, with Alic...

Jonah Comstock welcomed back Alice Valder Curran to the podcast to pick apart Trump's Executive Order order piece by piece.

Market Access

Medicines pricing, UK £20 notes with various pills

Buyer’s remorse: The UK’s VPAG

With the ABPI wanting to change the scheme just over a year into its five-year term, it seems that they have buyer’s remorse.

Deep Dive

Market Access

JCA readiness: How to prepare for success in the new EU HTA ...

Market Access

From market access to real-world patient access: Closing the...

Market Access

Demystifying market access: Inside the complex journey from ...

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

IQVIA Webinar on Innovative Medicines Fund

Sponsored

Innovative Medicines Fund and the opportunity for ICSs to mo...

Webinars

Sponsored

Medical Informatics and Rare Disease: a bridge between two w...

With more than 6,000 different diseases comprising the rare disease (RD) landscape, connecting patients and practitioners with the expertise needed to achieve th

Webinars

Sponsored

ICSs - an opportunity to improve Patient & Market Access at ...

With the new Health and Care Bill edging ever closer to receiving Royal Assent, life sciences companies in the UK are preparing to navigate the most significant piece of NHS legislation in

Podcasts

Market Access

Unpacking Trump’s executive order on drug pricing, with Alic...

Jonah Comstock welcomed back Alice Valder Curran to the podcast to pick apart Trump's Executive Order order piece by piece.

Market Access

IRA updates and making sense of the chaos in Washington, wit...

Market Access

Looking to history to prepare for America’s uncertain future

In this podcast episode, Jesse Mendelsohn and Nicole Raleigh discuss what the future might hold for pharma under a second Trump Administration

Video

Market Access

JP Morgan Week 2025 – Jeff Fischer

Market Access

Lori Fletcher and Amber Beimer, Advanced Clinical

Sponsored

Health Innovators: Lori Fletcher and Amber Beimer, Advanced ...

Clinical research is full of challenges, from recruitment to data management to global resourcing.

Market Access

Health Innovators – Aleks Engel

One month ago, editor-in-chief Jonah Comstock travelled to Copenhagen, Denmark to visit the Novo Nordisk Foundation.

White Papers

Spotlight on

Life Sciences Industry Report Part 1 Download

Life Sciences Industry Report 2025

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.

Market Access

Sponsored

Navigating Routes to Commercial Excellence in Cell and Gene ...

'Navigating Routes to Commercial Success in Cell and Gene Therapy', authored by Franjo Hanzl, VP, Business Development, Commercial at EVERSANA, Dr.

Debates & Insight

Sponsored

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need

Event

Market Access

Partner Content

6th Gene Therapy Analytical Development Summit Europe

Join 24+ expert speakers and over 90 industry stakeholders to unlock analytical strategies that elevate your development programmes,...

Market Access

Reuters Pharma Europe 2024

From the 16th to the 18th of April, industry leaders will gather in one of Spain’s most iconic cities as Reuters Pharma Europe returns for 2024.

Market Access

Reuters Pharma USA 2024 - Day 2

Wednesday brings much more Cell and Gene Therapy content, but we’ll also dip into the Marketing and Commercial tracks, looking at real-world evidence, value-based care, and omnichannel mark

Market Access

Sponsored

Innovative contracting in Europe – a Trojan horse?

Overview

Market Access

Sponsored

Launch excellence in a disrupted world – challenges & opport...

Overview

Market Access

Sponsored

Orphan medicines launch excellence: sustaining launch succes...

Overview Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.